Throughout 2021, the medical and scientific communities have focused on managing the
acute morbidity and mortality caused by the coronavirus disease 2019 (COVID-19) …

Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is …

Background Patients hospitalised with COVID-19 are at risk for thrombotic events after
discharge; the role of extended thromboprophylaxis in this population is unknown. Methods …

Background: Both SARS-CoV-2 and influenza virus share similarities such as clinical
features and outcome, laboratory, and radiological findings. Methods: Literature search was …

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

COVID-19 is associated with endothelial activation in the setting of a potent inflammatory
reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an …

Background Patients with COVID-19 infection are commonly reported to have an increased
risk of venous thrombosis. The choice of anti-thrombotic agents and doses are currently …

Background Data on thrombosis and current real-world management strategies for
anticoagulation therapy are scarce but important for understanding current issues and …

Based on emerging evidence from the COVID-19 pandemic, the International Society on
Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 …

The independent role of hypertension for COVID-19 outcomes in the population remains
unclear. We aimed to estimate the independent effect of hypertension and hypertension …